Unknown

Dataset Information

0

Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice.


ABSTRACT: Pre-existing antibodies that bind polyethylene glycol are present in about 40% of healthy individuals. It is currently unknown if pre-existing anti-polyethylene glycol (PEG) antibodies can alter the bioactivity of pegylated drugs with a single long PEG chain, which represents the majority of newly developed pegylated medicines. Methoxy polyethylene glycol-epoetin beta (PEG-EPO) contains a single 30 kDa PEG chain and is used to treat patients suffering from anemia. We find that the pre-existing human anti-PEG IgM and IgG antibodies from normal donors can bind to PEG-EPO. The prevalence and concentrations of anti-PEG IgM and IgG antibodies were also higher in patients that responded poorly to PEG-EPO. Monoclonal anti-PEG IgM and IgG antibodies at concentrations found in normal donors blocked the biological activity of PEG-EPO to stimulate the production of new erythrocytes in mice and accelerated the clearance of 125I-PEG-EPO, resulting in PEG-EPO accumulation primarily in the liver and spleen. Accelerated clearance by the anti-PEG IgG antibody was mediated by the Fc portion of the antibody. Importantly, infusing higher doses of PEG-EPO could compensate for the inhibitory effects of anti-PEG antibodies, suggesting that pre-existing anti-PEG antibodies can be "dosed through." Our study indicates that the bioactivity and therapeutic activity of PEG-EPO may be reduced in patients with elevated levels of pre-existing anti-PEG antibodies. New pegylated medicines with a single long PEG chain may also be affected in patients with high levels of anti-PEG antibodies.

SUBMITTER: Chang TC 

PROVIDER: S-EPMC7022322 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice.

Chang Tien-Ching TC   Chen Bing-Mae BM   Lin Wen-Wei WW   Yu Pei-Hua PH   Chiu Yi-Wen YW   Chen Yuan-Tsong YT   Wu Jer-Yuarn JY   Cheng Tian-Lu TL   Hwang Daw-Yang DY   Roffler And Steve AS  

Pharmaceutics 20191221 1


Pre-existing antibodies that bind polyethylene glycol are present in about 40% of healthy individuals. It is currently unknown if pre-existing anti-polyethylene glycol (PEG) antibodies can alter the bioactivity of pegylated drugs with a single long PEG chain, which represents the majority of newly developed pegylated medicines. Methoxy polyethylene glycol-epoetin beta (PEG-EPO) contains a single 30 kDa PEG chain and is used to treat patients suffering from anemia. We find that the pre-existing h  ...[more]

Similar Datasets

| S-EPMC6512330 | biostudies-literature
| S-EPMC7098874 | biostudies-literature
| S-EPMC2989790 | biostudies-literature
| S-EPMC6895480 | biostudies-literature
| S-EPMC2168164 | biostudies-literature
| S-EPMC6171506 | biostudies-literature
| S-EPMC4373866 | biostudies-literature
| S-EPMC10384409 | biostudies-literature
| S-EPMC9340711 | biostudies-literature
| S-EPMC7787990 | biostudies-literature